Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome
A combination of chemotherapy with immunotherapy has been proposed to have better
clinical outcomes in Pancreatic Ductal Adenocarcinoma (PDAC). On the other hand …
clinical outcomes in Pancreatic Ductal Adenocarcinoma (PDAC). On the other hand …
[HTML][HTML] Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non–Small Cell Lung Cancer: Real-World Effectiveness Versus Trial …
MV Verschueren, BJM Peters, LT Bloem, VR Kruik… - Clinical lung cancer, 2024 - Elsevier
Background Clinical trial efficacy and real-world effectiveness of oncological treatments can
differ. This study assessed the real-world survival outcomes of first-line pembrolizumab plus …
differ. This study assessed the real-world survival outcomes of first-line pembrolizumab plus …
Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study
MR Firoozi, S Sadeghi‐Mohammadi… - Cell Biochemistry …, 2024 - Wiley Online Library
Immunotherapy has lately become the most preferred cancer treatment method, and for non‐
small cell lung cancer (NSCLC) first‐line treatment, there are many immunotherapy options …
small cell lung cancer (NSCLC) first‐line treatment, there are many immunotherapy options …
Extracellular vesicles from lung adenocarcinoma cells induce activation of different CAF subtypes
JA Trejo Vazquez - 2024 - open.library.ubc.ca
Lung cancer is the leading cause of cancer deaths worldwide, largely due to metastasis. Its
main subtype is lung adenocarcinoma (LUAD). Communication between cancer cells and …
main subtype is lung adenocarcinoma (LUAD). Communication between cancer cells and …